An intranasal fentanyl spray (Instanyl) has been launched for the treatment of breakthrough pain experienced by patients with cancer.
The spray can be used by patients who are already taking maintenance opioid therapy for chronic cancer pain.
Maintenance therapy is defined as at least:
- 60 mg of oral morphine daily,
- 25 micrograms of transdermal fentanyl per hour,
- 30 mg oxycodone daily,
- 8 mg of oral hydromorphone daily
- or an equilivent dose of another opioid for a week or longer.